EGFR and central nervous system cancer: This study compared tumor tissues with 1p19q codeletion vs. EGFR amplification, and found that CRNDE expression was 37-fold higher in the latter and at levels comparable to those seen in CRNDE-expressing gliomas (i.e., glioblastomas, astroblastomas, and astrocytomas); expression in tumors with the codeletion was very low.